http://142-54-23-223.fusionmedialtd.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Wed, 19 Aug 2026 19:23:00 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://142-54-23-223.fusionmedialtd.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Penumbra+Inc++++++++++++++For%3A+Aug+17++Filed+by%3A+Narayan+Shruthi/26951543.html si-local-file:///var/storage/secattach/20260819/26951543.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Penumbra+Inc++++++++++++++For%3A+Aug+17++Filed+by%3A+Narayan+Shruthi/26951543.html Wed, 19 Aug 2026 19:23:00 -0400 O.01770044 PEN http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Penumbra+Inc++++++++++++++For%3A+Aug+17++Filed+by%3A+Narayan+Shruthi/26951543.html si-local-file:///var/storage/secattach/20260819/26951543.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Penumbra+Inc++++++++++++++For%3A+Aug+17++Filed+by%3A+Narayan+Shruthi/26951543.html Wed, 19 Aug 2026 19:23:00 -0400 O.01770044 PEN http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13G++Penumbra+Inc+++++++++++++++++++++++++++Filed+by%3A+BARCLAYS+PLC/26923086.html si-local-file:///var/storage/secattach/20260813/26923086.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13G++Penumbra+Inc+++++++++++++++++++++++++++Filed+by%3A+BARCLAYS+PLC/26923086.html Thu, 13 Aug 2026 18:48:00 -0400 O.01770044 PEN http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13G++Penumbra+Inc+++++++++++++++++++++++++++Filed+by%3A+BARCLAYS+PLC/26923086.html si-local-file:///var/storage/secattach/20260813/26923086.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13G++Penumbra+Inc+++++++++++++++++++++++++++Filed+by%3A+BARCLAYS+PLC/26923086.html Thu, 13 Aug 2026 18:48:00 -0400 O.01770044 PEN http://www.streetinsider.com/Earnings/Penumbra%2C+Inc.+%28PEN%29+Misses+Q2+EPS+by+28c/26844675.html <p>Penumbra, Inc. (NYSE: PEN) reported Q2 EPS of $0.88, $0.28 worse than the analyst estimate of $1.16. Revenue for the quarter came in at $390.04 million versus the consensus estimate of $389.61 million.</p><p>For earnings history and earnings-related data on Penumbra, Inc. (PEN) <a href="http://www.streetinsider.com/ec_earnings.php?q=PEN">click here</a>.</p> http://www.streetinsider.com/Earnings/Penumbra%2C+Inc.+%28PEN%29+Misses+Q2+EPS+by+28c/26844675.html Thu, 30 Jul 2026 17:00:27 -0400 PEN http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++Penumbra+Inc++++++++++++++For%3A+Jun+30/26844481.html si-local-file:///var/storage/secattach/20260730/26844481.html http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++Penumbra+Inc++++++++++++++For%3A+Jun+30/26844481.html Thu, 30 Jul 2026 16:45:00 -0400 O.01770044 PEN http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++Penumbra+Inc++++++++++++++For%3A+Jun+30/26844481.html si-local-file:///var/storage/secattach/20260730/26844481.html http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++Penumbra+Inc++++++++++++++For%3A+Jun+30/26844481.html Thu, 30 Jul 2026 16:45:00 -0400 O.01770044 PEN http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Penumbra+Inc++++++++++++++For%3A+Jul+30/26843770.html si-local-file:///var/storage/secattach/20260730/26843770.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Penumbra+Inc++++++++++++++For%3A+Jul+30/26843770.html Thu, 30 Jul 2026 16:14:00 -0400 O.01770044 PEN http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Penumbra+Inc++++++++++++++For%3A+Jul+30/26843770.html si-local-file:///var/storage/secattach/20260730/26843770.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Penumbra+Inc++++++++++++++For%3A+Jul+30/26843770.html Thu, 30 Jul 2026 16:14:00 -0400 O.01770044 PEN http://www.streetinsider.com/Press+Releases/Penumbra%2C+Inc.+Reports+Second+Quarter+2026+Financial+Results/26843462.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.ca.alaeda" idsrc="xmltag.org" >ALAMEDA, Calif.</location></span>, <span class="legendSpanClass"><chron>July 30, 2026</chron></span> /PRNewswire/ -- <span value="NYSE:PEN" idsrc="xmltag.org" >Penumbra, Inc.</span> (NYSE: PEN), the world's leading thrombectomy company, today reported financial results for the second quarter ended <chron>June 30, 2026</chron>.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> <p> <img src="https://mmx.prnewswire.com/media/MS1127088/Penumbra-Inc-Logo.jpg?id=OA2800381" title="Penumbra, Inc." alt="Penumbra, Inc." /> </p> http://www.streetinsider.com/Press+Releases/Penumbra%2C+Inc.+Reports+Second+Quarter+2026+Financial+Results/26843462.html Thu, 30 Jul 2026 16:05:00 -0400 BSX O.00016491 O.01770044 PEN http://www.streetinsider.com/Press+Releases/Penumbra%2C+Inc.+Reports+Second+Quarter+2026+Financial+Results/26843462.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.ca.alaeda" idsrc="xmltag.org" >ALAMEDA, Calif.</location></span>, <span class="legendSpanClass"><chron>July 30, 2026</chron></span> /PRNewswire/ -- <span value="NYSE:PEN" idsrc="xmltag.org" >Penumbra, Inc.</span> (NYSE: PEN), the world's leading thrombectomy company, today reported financial results for the second quarter ended <chron>June 30, 2026</chron>.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> <p> <img src="https://mmx.prnewswire.com/media/MS1127088/Penumbra-Inc-Logo.jpg?id=OA2800381" title="Penumbra, Inc." alt="Penumbra, Inc." /> </p> http://www.streetinsider.com/Press+Releases/Penumbra%2C+Inc.+Reports+Second+Quarter+2026+Financial+Results/26843462.html Thu, 30 Jul 2026 16:05:00 -0400 BSX O.00016491 O.01770044 PEN http://www.streetinsider.com/Press+Releases/Penumbra%2C+Inc.+Reports+Second+Quarter+2026+Financial+Results/26843462.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.ca.alaeda" idsrc="xmltag.org" >ALAMEDA, Calif.</location></span>, <span class="legendSpanClass"><chron>July 30, 2026</chron></span> /PRNewswire/ -- <span value="NYSE:PEN" idsrc="xmltag.org" >Penumbra, Inc.</span> (NYSE: PEN), the world's leading thrombectomy company, today reported financial results for the second quarter ended <chron>June 30, 2026</chron>.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> <p> <img src="https://mmx.prnewswire.com/media/MS1127088/Penumbra-Inc-Logo.jpg?id=OA2800381" title="Penumbra, Inc." alt="Penumbra, Inc." /> </p> http://www.streetinsider.com/Press+Releases/Penumbra%2C+Inc.+Reports+Second+Quarter+2026+Financial+Results/26843462.html Thu, 30 Jul 2026 16:05:00 -0400 BSX O.00016491 O.01770044 PEN http://www.streetinsider.com/Press+Releases/Penumbra%2C+Inc.+Reports+Second+Quarter+2026+Financial+Results/26843462.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.ca.alaeda" idsrc="xmltag.org" >ALAMEDA, Calif.</location></span>, <span class="legendSpanClass"><chron>July 30, 2026</chron></span> /PRNewswire/ -- <span value="NYSE:PEN" idsrc="xmltag.org" >Penumbra, Inc.</span> (NYSE: PEN), the world's leading thrombectomy company, today reported financial results for the second quarter ended <chron>June 30, 2026</chron>.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> <p> <img src="https://mmx.prnewswire.com/media/MS1127088/Penumbra-Inc-Logo.jpg?id=OA2800381" title="Penumbra, Inc." alt="Penumbra, Inc." /> </p> http://www.streetinsider.com/Press+Releases/Penumbra%2C+Inc.+Reports+Second+Quarter+2026+Financial+Results/26843462.html Thu, 30 Jul 2026 16:05:00 -0400 BSX O.00016491 O.01770044 PEN http://www.streetinsider.com/PRNewswire/Penumbra%2C+Inc.+Reports+Second+Quarter+2026+Financial+Results/26843462.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.ca.alaeda" idsrc="xmltag.org" >ALAMEDA, Calif.</location></span>, <span class="legendSpanClass"><chron>July 30, 2026</chron></span> /PRNewswire/ -- <span value="NYSE:PEN" idsrc="xmltag.org" >Penumbra, Inc.</span> (NYSE: PEN), the world's leading thrombectomy company, today reported financial results for the second quarter ended <chron>June 30, 2026</chron>.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> <p> <img src="https://mmx.prnewswire.com/media/MS1127088/Penumbra-Inc-Logo.jpg?id=OA2800381" title="Penumbra, Inc." alt="Penumbra, Inc." /> </p> http://www.streetinsider.com/PRNewswire/Penumbra%2C+Inc.+Reports+Second+Quarter+2026+Financial+Results/26843462.html Thu, 30 Jul 2026 16:05:00 -0400 BSX O.00016491 O.01770044 PEN http://www.streetinsider.com/PRNewswire/Penumbra%2C+Inc.+Reports+Second+Quarter+2026+Financial+Results/26843462.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.ca.alaeda" idsrc="xmltag.org" >ALAMEDA, Calif.</location></span>, <span class="legendSpanClass"><chron>July 30, 2026</chron></span> /PRNewswire/ -- <span value="NYSE:PEN" idsrc="xmltag.org" >Penumbra, Inc.</span> (NYSE: PEN), the world's leading thrombectomy company, today reported financial results for the second quarter ended <chron>June 30, 2026</chron>.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> <p> <img src="https://mmx.prnewswire.com/media/MS1127088/Penumbra-Inc-Logo.jpg?id=OA2800381" title="Penumbra, Inc." alt="Penumbra, Inc." /> </p> http://www.streetinsider.com/PRNewswire/Penumbra%2C+Inc.+Reports+Second+Quarter+2026+Financial+Results/26843462.html Thu, 30 Jul 2026 16:05:00 -0400 BSX O.00016491 O.01770044 PEN http://www.streetinsider.com/PRNewswire/Penumbra%2C+Inc.+Reports+Second+Quarter+2026+Financial+Results/26843462.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.ca.alaeda" idsrc="xmltag.org" >ALAMEDA, Calif.</location></span>, <span class="legendSpanClass"><chron>July 30, 2026</chron></span> /PRNewswire/ -- <span value="NYSE:PEN" idsrc="xmltag.org" >Penumbra, Inc.</span> (NYSE: PEN), the world's leading thrombectomy company, today reported financial results for the second quarter ended <chron>June 30, 2026</chron>.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> <p> <img src="https://mmx.prnewswire.com/media/MS1127088/Penumbra-Inc-Logo.jpg?id=OA2800381" title="Penumbra, Inc." alt="Penumbra, Inc." /> </p> http://www.streetinsider.com/PRNewswire/Penumbra%2C+Inc.+Reports+Second+Quarter+2026+Financial+Results/26843462.html Thu, 30 Jul 2026 16:05:00 -0400 BSX O.00016491 O.01770044 PEN http://www.streetinsider.com/PRNewswire/Penumbra%2C+Inc.+Reports+Second+Quarter+2026+Financial+Results/26843462.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.ca.alaeda" idsrc="xmltag.org" >ALAMEDA, Calif.</location></span>, <span class="legendSpanClass"><chron>July 30, 2026</chron></span> /PRNewswire/ -- <span value="NYSE:PEN" idsrc="xmltag.org" >Penumbra, Inc.</span> (NYSE: PEN), the world's leading thrombectomy company, today reported financial results for the second quarter ended <chron>June 30, 2026</chron>.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> <p> <img src="https://mmx.prnewswire.com/media/MS1127088/Penumbra-Inc-Logo.jpg?id=OA2800381" title="Penumbra, Inc." alt="Penumbra, Inc." /> </p> http://www.streetinsider.com/PRNewswire/Penumbra%2C+Inc.+Reports+Second+Quarter+2026+Financial+Results/26843462.html Thu, 30 Jul 2026 16:05:00 -0400 BSX O.00016491 O.01770044 PEN http://www.streetinsider.com/Corporate+News/Penumbra+study+shows+THUNDERBOLT+met+stroke+treatment+goals/26801057.html <p>Penumbra, Inc. (NYSE: PEN) announced results from the THUNDER study, an Investigational Device Exemption trial evaluating its THUNDERBOLT computer assisted vacuum thrombectomy (CAVT) system in stroke patients with emergent large vessel occlusion (ELVO). The data were presented at the Society of NeuroInterventional Surgery 23rd Annual Meeting.</p><p>The study met its predefined performance goal, with 87.5% of cases achieving successful reperfusion, defined as mTICI 2b-3, following treatment with THUNDERBOLT. Post-procedure, mTICI 2c-3 was achieved in 70.4% of cases. Additional results included a first-pass mTICI 2b-3 rate of 64.8%, a median time-to-revascularization of 20 minutes, and a complete clot ingestion rate of 83%.</p><p>Device http://www.streetinsider.com/Corporate+News/Penumbra+study+shows+THUNDERBOLT+met+stroke+treatment+goals/26801057.html Wed, 22 Jul 2026 14:36:03 -0400 PEN http://www.streetinsider.com/FDA/Penumbra+study+shows+THUNDERBOLT+met+stroke+treatment+goals/26801057.html <p>Penumbra, Inc. (NYSE: PEN) announced results from the THUNDER study, an Investigational Device Exemption trial evaluating its THUNDERBOLT computer assisted vacuum thrombectomy (CAVT) system in stroke patients with emergent large vessel occlusion (ELVO). The data were presented at the Society of NeuroInterventional Surgery 23rd Annual Meeting.</p><p>The study met its predefined performance goal, with 87.5% of cases achieving successful reperfusion, defined as mTICI 2b-3, following treatment with THUNDERBOLT. Post-procedure, mTICI 2c-3 was achieved in 70.4% of cases. Additional results included a first-pass mTICI 2b-3 rate of 64.8%, a median time-to-revascularization of 20 minutes, and a complete clot ingestion rate of 83%.</p><p>Device http://www.streetinsider.com/FDA/Penumbra+study+shows+THUNDERBOLT+met+stroke+treatment+goals/26801057.html Wed, 22 Jul 2026 14:36:03 -0400 PEN http://www.streetinsider.com/Press+Releases/THUNDER+Study+Demonstrates+Penumbra%27s+THUNDERBOLT+is+Safe+and+Effective+for+Stroke+Care/26801055.html <div class="xn-content"> <p class="prntac"><i>First and only CAVT device for stroke demonstrated high revascularization rates, short procedure times and low complication rates</i></p><p><span class="legendSpanClass"><location value="LU/us.ca.alaeda" idsrc="xmltag.org" >ALAMEDA, Calif.</location></span>, <span class="legendSpanClass"><chron>July 22, 2026</chron></span> /PRNewswire/ -- <a target="_blank" href="https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4737069-1&amp;h=3006766717&amp;u=https%3A%2F%2Fwww.penumbrainc.com%2F&amp;a=Penumbra%2C+Inc" target="_blank" rel="nofollow"><span value="NYSE:PEN" idsrc="xmltag.org" >Penumbra, Inc</span></a>. (NYSE: PEN), the world's leading thrombectomy company, announced the results of THUNDER, an Investigational Device Exemption (IDE) study, to evaluate the safety and effectiveness of THUNDERBOLT™, the company's novel computer assisted vacuum thrombectomy (CAVT™) system, in stroke patients with emergent large vessel occlusion (ELVO). The data were presented this week during a late-breaking session at the <span>Society of NeuroInterventional Surgery</span> (SNIS) 23rd Annual Meeting.</p> http://www.streetinsider.com/Press+Releases/THUNDER+Study+Demonstrates+Penumbra%27s+THUNDERBOLT+is+Safe+and+Effective+for+Stroke+Care/26801055.html Wed, 22 Jul 2026 14:35:00 -0400 A.07275906 O.01770044 O.31842592 PEN http://www.streetinsider.com/Press+Releases/THUNDER+Study+Demonstrates+Penumbra%27s+THUNDERBOLT+is+Safe+and+Effective+for+Stroke+Care/26801055.html <div class="xn-content"> <p class="prntac"><i>First and only CAVT device for stroke demonstrated high revascularization rates, short procedure times and low complication rates</i></p><p><span class="legendSpanClass"><location value="LU/us.ca.alaeda" idsrc="xmltag.org" >ALAMEDA, Calif.</location></span>, <span class="legendSpanClass"><chron>July 22, 2026</chron></span> /PRNewswire/ -- <a target="_blank" href="https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4737069-1&amp;h=3006766717&amp;u=https%3A%2F%2Fwww.penumbrainc.com%2F&amp;a=Penumbra%2C+Inc" target="_blank" rel="nofollow"><span value="NYSE:PEN" idsrc="xmltag.org" >Penumbra, Inc</span></a>. (NYSE: PEN), the world's leading thrombectomy company, announced the results of THUNDER, an Investigational Device Exemption (IDE) study, to evaluate the safety and effectiveness of THUNDERBOLT™, the company's novel computer assisted vacuum thrombectomy (CAVT™) system, in stroke patients with emergent large vessel occlusion (ELVO). The data were presented this week during a late-breaking session at the <span>Society of NeuroInterventional Surgery</span> (SNIS) 23rd Annual Meeting.</p> http://www.streetinsider.com/Press+Releases/THUNDER+Study+Demonstrates+Penumbra%27s+THUNDERBOLT+is+Safe+and+Effective+for+Stroke+Care/26801055.html Wed, 22 Jul 2026 14:35:00 -0400 A.07275906 O.01770044 O.31842592 PEN http://www.streetinsider.com/Press+Releases/THUNDER+Study+Demonstrates+Penumbra%27s+THUNDERBOLT+is+Safe+and+Effective+for+Stroke+Care/26801055.html <div class="xn-content"> <p class="prntac"><i>First and only CAVT device for stroke demonstrated high revascularization rates, short procedure times and low complication rates</i></p><p><span class="legendSpanClass"><location value="LU/us.ca.alaeda" idsrc="xmltag.org" >ALAMEDA, Calif.</location></span>, <span class="legendSpanClass"><chron>July 22, 2026</chron></span> /PRNewswire/ -- <a target="_blank" href="https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4737069-1&amp;h=3006766717&amp;u=https%3A%2F%2Fwww.penumbrainc.com%2F&amp;a=Penumbra%2C+Inc" target="_blank" rel="nofollow"><span value="NYSE:PEN" idsrc="xmltag.org" >Penumbra, Inc</span></a>. (NYSE: PEN), the world's leading thrombectomy company, announced the results of THUNDER, an Investigational Device Exemption (IDE) study, to evaluate the safety and effectiveness of THUNDERBOLT™, the company's novel computer assisted vacuum thrombectomy (CAVT™) system, in stroke patients with emergent large vessel occlusion (ELVO). The data were presented this week during a late-breaking session at the <span>Society of NeuroInterventional Surgery</span> (SNIS) 23rd Annual Meeting.</p> http://www.streetinsider.com/Press+Releases/THUNDER+Study+Demonstrates+Penumbra%27s+THUNDERBOLT+is+Safe+and+Effective+for+Stroke+Care/26801055.html Wed, 22 Jul 2026 14:35:00 -0400 A.07275906 O.01770044 O.31842592 PEN http://www.streetinsider.com/Press+Releases/THUNDER+Study+Demonstrates+Penumbra%27s+THUNDERBOLT+is+Safe+and+Effective+for+Stroke+Care/26801055.html <div class="xn-content"> <p class="prntac"><i>First and only CAVT device for stroke demonstrated high revascularization rates, short procedure times and low complication rates</i></p><p><span class="legendSpanClass"><location value="LU/us.ca.alaeda" idsrc="xmltag.org" >ALAMEDA, Calif.</location></span>, <span class="legendSpanClass"><chron>July 22, 2026</chron></span> /PRNewswire/ -- <a target="_blank" href="https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4737069-1&amp;h=3006766717&amp;u=https%3A%2F%2Fwww.penumbrainc.com%2F&amp;a=Penumbra%2C+Inc" target="_blank" rel="nofollow"><span value="NYSE:PEN" idsrc="xmltag.org" >Penumbra, Inc</span></a>. (NYSE: PEN), the world's leading thrombectomy company, announced the results of THUNDER, an Investigational Device Exemption (IDE) study, to evaluate the safety and effectiveness of THUNDERBOLT™, the company's novel computer assisted vacuum thrombectomy (CAVT™) system, in stroke patients with emergent large vessel occlusion (ELVO). The data were presented this week during a late-breaking session at the <span>Society of NeuroInterventional Surgery</span> (SNIS) 23rd Annual Meeting.</p> http://www.streetinsider.com/Press+Releases/THUNDER+Study+Demonstrates+Penumbra%27s+THUNDERBOLT+is+Safe+and+Effective+for+Stroke+Care/26801055.html Wed, 22 Jul 2026 14:35:00 -0400 A.07275906 O.01770044 O.31842592 PEN http://www.streetinsider.com/PRNewswire/THUNDER+Study+Demonstrates+Penumbra%27s+THUNDERBOLT+is+Safe+and+Effective+for+Stroke+Care/26801055.html <div class="xn-content"> <p class="prntac"><i>First and only CAVT device for stroke demonstrated high revascularization rates, short procedure times and low complication rates</i></p><p><span class="legendSpanClass"><location value="LU/us.ca.alaeda" idsrc="xmltag.org" >ALAMEDA, Calif.</location></span>, <span class="legendSpanClass"><chron>July 22, 2026</chron></span> /PRNewswire/ -- <a target="_blank" href="https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4737069-1&amp;h=3006766717&amp;u=https%3A%2F%2Fwww.penumbrainc.com%2F&amp;a=Penumbra%2C+Inc" target="_blank" rel="nofollow"><span value="NYSE:PEN" idsrc="xmltag.org" >Penumbra, Inc</span></a>. (NYSE: PEN), the world's leading thrombectomy company, announced the results of THUNDER, an Investigational Device Exemption (IDE) study, to evaluate the safety and effectiveness of THUNDERBOLT™, the company's novel computer assisted vacuum thrombectomy (CAVT™) system, in stroke patients with emergent large vessel occlusion (ELVO). The data were presented this week during a late-breaking session at the <span>Society of NeuroInterventional Surgery</span> (SNIS) 23rd Annual Meeting.</p> http://www.streetinsider.com/PRNewswire/THUNDER+Study+Demonstrates+Penumbra%27s+THUNDERBOLT+is+Safe+and+Effective+for+Stroke+Care/26801055.html Wed, 22 Jul 2026 14:35:00 -0400 A.07275906 O.01770044 O.31842592 PEN http://www.streetinsider.com/PRNewswire/THUNDER+Study+Demonstrates+Penumbra%27s+THUNDERBOLT+is+Safe+and+Effective+for+Stroke+Care/26801055.html <div class="xn-content"> <p class="prntac"><i>First and only CAVT device for stroke demonstrated high revascularization rates, short procedure times and low complication rates</i></p><p><span class="legendSpanClass"><location value="LU/us.ca.alaeda" idsrc="xmltag.org" >ALAMEDA, Calif.</location></span>, <span class="legendSpanClass"><chron>July 22, 2026</chron></span> /PRNewswire/ -- <a target="_blank" href="https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4737069-1&amp;h=3006766717&amp;u=https%3A%2F%2Fwww.penumbrainc.com%2F&amp;a=Penumbra%2C+Inc" target="_blank" rel="nofollow"><span value="NYSE:PEN" idsrc="xmltag.org" >Penumbra, Inc</span></a>. (NYSE: PEN), the world's leading thrombectomy company, announced the results of THUNDER, an Investigational Device Exemption (IDE) study, to evaluate the safety and effectiveness of THUNDERBOLT™, the company's novel computer assisted vacuum thrombectomy (CAVT™) system, in stroke patients with emergent large vessel occlusion (ELVO). The data were presented this week during a late-breaking session at the <span>Society of NeuroInterventional Surgery</span> (SNIS) 23rd Annual Meeting.</p> http://www.streetinsider.com/PRNewswire/THUNDER+Study+Demonstrates+Penumbra%27s+THUNDERBOLT+is+Safe+and+Effective+for+Stroke+Care/26801055.html Wed, 22 Jul 2026 14:35:00 -0400 A.07275906 O.01770044 O.31842592 PEN